30194-9/asset/e2a34f3b-6f8a-425f-9e34-2cf394cbb616/main.assets/gr4_lrg.jpg)
oral semaglutide efficacy and safety of with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial Oral semaglutide found to lower
Description
Small increases in training load (~30 mins above your usual baseline) show minimal impact on recovery metrics
Scientists don't fully understand the mechanism yet, but people taking GLP-1 drugs tend to eat less ultra-processed food, more fibre, fruit and vegetables, smaller portions, and fewer snacks
Just results
Pricing, eligibility, and program terms can change - verify current terms on mademed.com
This was prompted by the publication of a landmark article in the New England Journal of Medicine addressing the impact of this medication in a large clinical trial
